Articles Tagged With: LDL
-
Bempedoic Acid (Nexletol) and Bempedoic Acid and Ezetimibe (Nexlizet)
The U.S. Food and Drug Administration is expected to update the indications for bempedoic acid and bempedoic acid/ezetimibe. Esperion has submitted clinical evidence in the form of Cholesterol Lowering via Bempedoic Acid an ACL-inhibiting Regimen (CLEAR) that demonstrated that bempedoic acid was associated with a lower risk of major adverse cardiovascular events compared to placebo. Bempedoic acid and bempedoic acid/ezetimibe are distributed by Esperion as Nexletol and Nexlizet, respectively.
-
Safety and Tolerability of Inclisiran
A pooled analysis of seven relatively short-term ORION studies of inclisiran vs. placebo for lowering low-density lipoprotein cholesterol that assessed safety and tolerability for up to six years showed that inclisiran has similar rates of adverse events, excluding injection site reactions, as placebo treatment and is associated with fewer major adverse cardiovascular events.
-
Safety and Tolerability of Inclisiran
A pooled analysis of seven relatively short-term ORION studies of inclisiran vs. placebo for lowering low-density lipoprotein cholesterol that assessed safety and tolerability for up to six years showed that inclisiran has similar rates of adverse events, excluding injection site reactions, as placebo treatment and is associated with fewer major adverse cardiovascular events.
-
Cholesterol Levels and Predicted Survival Rates Among Elderly Women
Researchers found neither low levels of high-density lipoprotein nor high levels of low-density lipoprotein were associated with predicted survival in older women. This finding is consistent with other studies of cholesterol and mortality in the elderly.